Find verified Resmetirom API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Resmetirom for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Resmetirom API.
Alternate Names: 920509-32-6, VIA-3196, Rezdiffra
CAS No: 920509-32-6
Mol Formula: C17H12Cl2N6O4
Mol Weight: 435.2 g/mol
IUPAC Name: 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile
API Description: Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD. Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation.
